Short Interest in Click Holdings Limited (NASDAQ:CLIK) Declines By 48.6%

Click Holdings Limited (NASDAQ:CLIK) saw a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 50,211 shares, a decline of 48.6% from the May 14th total of 97,673 shares. Approximately 4.4% of the shares of the company are sold short. Based on an average daily trading volume, of 1,195,878 shares, the short-interest ratio is presently 0.0 days.

Click Price Performance

NASDAQ:CLIK opened at $1.57 on Tuesday. The stock’s 50 day simple moving average is $2.12 and its 200-day simple moving average is $3.55. Click has a 12-month low of $1.32 and a 12-month high of $15.90.

Click (NASDAQ:CLIK) last released its earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $3.79 million during the quarter.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Wall Street Zen raised Click to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Click in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Click

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC purchased a new position in shares of Click Holdings Limited (NASDAQ:CLIK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned 1.23% of Click as of its most recent SEC filing.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.